Radical improvement in cancer care can be accomplished by individualizing patient management via the application of genomics and functional model systems into clinical practice. Recent breakthroughs in immunotherapy (i.e. checkpoint inhibitors) and targeted therapies (i.e. NTRK inhibitors) have shown that therapy of advanced cancers might become agnostic to the organ of origin, arguing for a more individualized approach to patient care. Emerging genomics technologies, data integration and visualization platforms are powerful tools to determine the state of the individual's tumor and point to tailored treatments. Furthermore, an efficient combination of comprehensive genomics with 3D microcancer functional model systems can further refine treatment decisions. However, applying such disruptive technologies in clinical practice is not trivial. Regulatory, financial and clinical barriers will be discussed.
展开▼